Lygenesis
Biotechnology · Regenerative Medicine
$25.8Mtotal raised · 4 rounds on record
$17.8Mlatest round · Venture round · Oct 2023 · 3 yr ago
6team · US Form 5500 (plan participants) · Dec 2025 · +100% in a year
2017founded
Overview
About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs.
Key facts
These are the key facts about Lygenesis on Alion as of Nov 13, 2026. Lygenesis is headquartered in Pittsburgh, United States. It was founded in 2017. It has raised $25.8M in 4 funding rounds. The latest round is Venture - Series Unknown of $17.8M, announced in 2023.
- Headquarters
- Pittsburgh, United StatesAlion company profile, updated Oct 12, 2026
- Founded
- 2017Alion company profile, updated Oct 12, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $25.8MSum of 4 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $17.8M · Oct 5, 2023SEC Form D filing · sec.gov
Funding and backers
Total raised
$25.8M
4 rounds on record
Latest round
$17.8M
Venture round · Oct 2023 · 3 yr ago
Team
6
US Form 5500 (plan participants) · Dec 2025 · +100% in a year
The money's age
Long since its last round
37 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 5, 2023
Raised a round Venture round $17.8M · SEC Form D
Dec 14, 2020
Raised a round Venture round $1.9M · SEC Form D
Oct 18, 2019
Raised a round Venture round $4M · SEC Form D
May 9, 2018
Raised a round Venture round $2.2M · SEC Form D
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2023 | $17.8M | — | SEC Form D |
| Venture round | Dec 2020 | $1.9M | — | SEC Form D |
| Venture round | Oct 2019 | $4M | — | SEC Form D |
| Venture round | May 2018 | $2.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | LyGenesis Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paulo FontesExecutive OfficerSEC Form D
Eric LegasseExecutive OfficerSEC Form D
Michael HuffordExecutive Officer, DirectorSEC Form D
Eric LagasseExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
About Us Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene…
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
Dystrogen Therapeutics is a clinical-stage biotech company developing chimeric cell therapy for muscle wasting disorders such as Duchenne…
We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
People
Paulo Fontes
Executive Officer
Eric Legasse
Executive Officer
Michael Hufford
Executive Officer, Director
Eric Lagasse
Executive Officer, Director
Gregory Bailey
Director
James Mellon
Director
Steve Felstead
Director
Justin Briggs
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Pittsburgh
United States
HQ
50-200 est. staff
How to cite this page
Alion, "Lygenesis: key facts", as of Nov 13, 2026. https://alion.io/company/lygenesis
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0